Article Text

Download PDFPDF
Riociguat for pulmonary hypertension in congenital heart disease: opportunities and challenges

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Both authors contributed to the writing and critical review of the manuscript.

  • Competing interests AEL and G-PD have received grants from Actelion and Pfizer, UK and Global.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles